Clinical Trial Update: Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing EN3348 (mycobacterial cell wall-DNA complex) to mitomycin C for intravesical treatment of BCG-recurrent/refractory non-muscle invasive b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• EN3348 (Mycobacterial Cell Wall-DNA Complex)
• Mitomycin-C (mitomycin C)

Snippet

Sponsor: Bioniche Life Sciences Inc. | Conditions: Bladder Neoplasm, Neoplasm Recurrence, Local | Phase 3 | Status: TERMINATED | Results posted: 2014-09-11